Kevin Curran

Kevin Curran is a reporter for RealMoney.

Prior to joining RealMoney he was a Senior Reporter in the FT Specialist division of The Financial Times where he specialized in covering institutional investors.

Kevin is a graduate of Fordham University where he studied International Political Economy and English.

Recent Articles By The Author

Roger Stone Speculates on Trump's Trade Tactics

Roger Stone Speculates on Trump's Trade Tactics

Stone says Trump is just looking for a better deal.

Chart of the Day 2: North America Is the Big Battleground for Pepsi and Coke

Chart of the Day 2: North America Is the Big Battleground for Pepsi and Coke

Pepsi's clash with Coke is most pivotal closer to home.

Chart of the Day: Can Pepsi Push Past La Croix For Seltzer Sippers?

Chart of the Day: Can Pepsi Push Past La Croix For Seltzer Sippers?

is La Croix a conqueror or is Pepsi planning a coup?

Wall Street Sees Safe Stock Story for PepsiCo Under New CEO Laguarta

Wall Street Sees Safe Stock Story for PepsiCo Under New CEO Laguarta

Pepsi looks like a safe play to analysts.

PepsiCo Pops Post-Earnings in a Sharp Contrast to Rival Coke

PepsiCo Pops Post-Earnings in a Sharp Contrast to Rival Coke

A small dividend hike is helping to give PepsiCo shares a boost after its mixed earnings report.

Chart of the Day: How Correlative are Crypto Woes to Nvidia Stock?

Chart of the Day: How Correlative are Crypto Woes to Nvidia Stock?

Is crypto really crashing Nvidia stock?

What Apple's Pre-Announcement Experience Offers for Nvidia Watchers

What Apple's Pre-Announcement Experience Offers for Nvidia Watchers

What can Tim Cook's cuts to estimates tell us about Nvidia earnings and the stock's trajectory?

Everything You Need to Know About Nvidia Before Earnings

Everything You Need to Know About Nvidia Before Earnings

The big chipmaker and its CEO, Jensen Huang, need to reclaim investor trust on Thursday.

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva's CEO explains why 2019 is a trough year for the Israeli pharma company.

What Is Switching Investors on to Cisco Stock?

What Is Switching Investors on to Cisco Stock?

Cisco could surge with these key catalysts and indicators switched on.